Patient and Clinical Factors Associated With Response to Medications for Posttraumatic Stress Disorder

Brian Shiner, Jiang Gui, Luke Rozema, Sarah L. Cornelius, Vincent Dufort, Paula P. Schnurr, Bradley V. WattsThe Journal of Clinical Psychiatry 2021 · DOI

Abstract

Conclusions: In the largest real-world study of medications for PTSD to date, we did not observe a pattern of differential response among clinical subgroups. All patients taking medications for PTSD, especially those with the highest levels of disability, should consider combined treatment with evidence-based psychotherapy.

Introduction

Posttraumatic Stress Disorder (PTSD) is a debilitating condition that affects a significant portion of the veteran and civilian populations. While several medications, including Selective Serotonin Reuptake Inhibitors (SSRIs) like sertraline and paroxetine, are FDA-approved for treatment, clinical response varies widely. Clinicians often face the challenge of "medication selection," frequently relying on expert opinion or the presence of comorbidities (such as using topiramate for patients with concurrent headaches) to guide their choices.

This study aimed to determine whether specific patient factors—such as sex, race, or psychiatric comorbidities—predict a superior response to one of five commonly prescribed PTSD medications: fluoxetine, paroxetine, sertraline, topiramate, and venlafaxine.

Methods

Researchers conducted a retrospective cohort study using data from the Department of Veterans Affairs (VA) Corporate Data Warehouse (CDW). The study analyzed 6,839 VA outpatients treated between 1999 and 2019. To be included, patients had to complete an "Adequate Medication Trial," defined as at least 12 weeks at a therapeutic dose, and have recorded PTSD Checklist (PCL) scores at both baseline and the 12-week follow-up.

To overcome the limitations of unstructured electronic health records, the team utilized a custom Natural Language Processing (NLP) algorithm with 98% precision to extract PCL scores from clinical notes. To ensure a fair comparison between non-randomized groups, the researchers employed Propensity Score Weighting (via the TWANG toolkit) to balance dozens of covariates, including age, service history, and prior treatments. Finally, LASSO regression models were used to identify the strongest predictors of clinical improvement.

Key Results

The Finding of Medication Equivalence

Despite the different pharmacological profiles of the five drugs studied (SSRIs, an SNRI, and an anticonvulsant), the study found no significant differences in efficacy across clinical subgroups. All five medications produced a similar average improvement of approximately 10% in PTSD symptoms. Between 22.5% and 25.7% of patients achieved a "clinically meaningful improvement," defined as a 15-point reduction on the PCL scale.

Psychotherapy as a Treatment Multiplier

The most significant predictor of positive outcomes was not the specific medication chosen, but the concurrent receipt of evidence-based psychotherapy (such as Cognitive Processing Therapy). The data revealed that each session of individual psychotherapy increased the odds of achieving meaningful clinical improvement by approximately 8%.

The Impact of Disability and Severity

Interestingly, patients with higher baseline symptom scores were more likely to achieve a 15-point drop, likely due to having more "room to improve." Conversely, veterans with high VA disability ratings (70% or greater) were significantly less likely to show meaningful improvement. This suggests that patients with high levels of disability may face unique barriers to recovery, potentially including higher baseline treatment resistance.

Discussion

The lack of differential response across subgroups challenges the current practice of selecting PTSD medications based on patient demographics or specific psychiatric comorbidities. While a medication like topiramate might be chosen to address comorbid headaches, this study suggests it does not provide a superior benefit for PTSD symptoms specifically compared to SSRIs.

Limitations

As a retrospective study of primarily male veterans, the results may not be fully generalizable to civilian populations or women. Furthermore, the study focused exclusively on PTSD symptom reduction (PCL scores). It remains possible that specific medications offer advantages for other outcomes, such as sleep quality, pain management, or social functioning, which were not captured in this analysis.

Conclusion

In the largest real-world analysis of its kind, no single medication emerged as a clear winner for any specific patient subgroup. These findings suggest that for most patients, the choice between common PTSD medications can be guided by side-effect profiles and patient preference rather than an expectation of superior efficacy. Most importantly, the results underscore that medication should ideally be paired with evidence-based psychotherapy to maximize the chances of recovery.

Summary updated

Abstract

<b><i>Conclusions:</i></b> In the largest real-world study of medications for PTSD to date, we did not observe a pattern of differential response among clinical subgroups. All patients taking medications for PTSD, especially those with the highest levels of disability, should consider combined treatment with evidence-based psychotherapy.
BibTeX
@article{shiner2021patient,
  author = {Brian Shiner and Jiang Gui and Luke Rozema and Sarah L. Cornelius and Vincent Dufort and Paula P. Schnurr and Bradley V. Watts},
  title = {{Patient and Clinical Factors Associated With Response to Medications for Posttraumatic Stress Disorder}},
  journal = {The Journal of Clinical Psychiatry},
  year = {2021},
  doi = {10.4088/jcp.21m13913},
}
Figure